메뉴 건너뛰기




Volumn 74, Issue 4, 2014, Pages 739-750

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

Author keywords

Germ line polymorphism marker; Renal cell carcinoma; Serum marker; Sunitinib; Tumor marker

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB; TUMOR ANTIGEN; TUMOR MARKER; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

EID: 84925545307     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2539-0     Document Type: Article
Times cited : (67)

References (27)
  • 4
    • 84883440578 scopus 로고    scopus 로고
    • Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC)
    • (abstr. 10525)
    • Harmon CS, Figlin RA, Hutson, TE, Michaelson MD, Negrier S, Kim ST, Huang X, Williams JA, Motzer RM (2011) Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(Suppl) (abstr. 10525)
    • (2011) J Clin Oncol , vol.29
    • Harmon, C.S.1    Figlin, R.A.2    Hutson3    Michaelson, M.D.4    Negrier, S.5    Kim, S.T.6    Huang, X.7    Williams, J.A.8    Motzer, R.M.9
  • 5
    • 84864333467 scopus 로고    scopus 로고
    • Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials
    • 22759480 1:CAS:528:DC%2BC38XhtFajsLnF
    • Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13:827-837
    • (2012) Lancet Oncol , vol.13 , pp. 827-837
    • Tran, H.T.1    Liu, Y.2    Zurita, A.J.3    Lin, Y.4    Baker-Neblett, K.L.5    Martin, A.M.6    Figlin, R.A.7    Hutson, T.E.8    Sternberg, C.N.9    Amado, R.G.10    Pandite, L.N.11    Heymach, J.V.12
  • 8
    • 53749093040 scopus 로고    scopus 로고
    • Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    • on behalf of ECOG 2100 Erratum in: J Clin Oncol (2009) 27:3070
    • Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, on behalf of ECOG 2100 (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678. Erratum in: J Clin Oncol (2009) 27:3070
    • (2008) J Clin Oncol , vol.26 , pp. 4672-4678
    • Schneider, B.P.1    Wang, M.2    Radovich, M.3    Sledge, G.W.4    Badve, S.5    Thor, A.6    Flockhart, D.A.7    Hancock, B.8    Davidson, N.9    Gralow, J.10    Dickler, M.11    Perez, E.A.12    Cobleigh, M.13    Shenkier, T.14    Edgerton, S.15    Miller, K.D.16
  • 12
    • 77957570088 scopus 로고    scopus 로고
    • Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial
    • 20651059
    • Peña C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16:4853-4863
    • (2010) Clin Cancer Res , vol.16 , pp. 4853-4863
    • Peña, C.1    Lathia, C.2    Shan, M.3    Escudier, B.4    Bukowski, R.M.5
  • 13
    • 68549092780 scopus 로고    scopus 로고
    • Analysis of PTEN and HIF1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
    • 19526589 1:CAS:528:DC%2BD1MXhtVOnurnJ
    • Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G (2009) Analysis of PTEN and HIF1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α. Cancer 115:3651-3660
    • (2009) Cancer , vol.115 , pp. 3651-3660
    • Figlin, R.A.1    De Souza, P.2    McDermott, D.3    Dutcher, J.P.4    Berkenblit, A.5    Thiele, A.6    Krygowski, M.7    Strahs, A.8    Feingold, J.9    Boni, J.10    Hudes, G.11
  • 14
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • 11773181 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D
    • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
    • (2002) J Clin Oncol , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3    Russo, P.4    Mazumdar, M.5
  • 15
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • 10655437 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6    Verweij, J.7    Van Glabbeke, M.8    Van Oosterom, A.T.9    Christian, M.C.10    Gwyther, S.G.11
  • 17
    • 59749098453 scopus 로고    scopus 로고
    • 'Fit-for-purpose' validation for SearchLight Multiplex ELISAs of angiogenesis for clinical trial use
    • 19174166 1:CAS:528:DC%2BD1MXitVCnt7k%3D
    • Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C (2009) 'Fit-for-purpose' validation for SearchLight Multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods 342:106-114
    • (2009) J Immunol Methods , vol.342 , pp. 106-114
    • Backen, A.C.1    Cummings, J.2    Mitchell, C.3    Jayson, G.4    Ward, T.H.5    Dive, C.6
  • 19
    • 8444239305 scopus 로고    scopus 로고
    • VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
    • 15541813
    • Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293-298
    • (2004) Lung Cancer , vol.46 , pp. 293-298
    • Koukourakis, M.I.1    Papazoglou, D.2    Giatromanolaki, A.3    Bougioukas, G.4    Maltezos, E.5    Sivridis, E.6
  • 21
    • 0001677717 scopus 로고
    • Controlling the false discovery rate: A practical and powerful approach to multiple testing
    • Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57:289-300
    • (1995) J R Stat Soc ser B (Methodological) , vol.57 , pp. 289-300
    • Benjamini, Y.1    Hochberg, Y.2
  • 23
    • 84869407359 scopus 로고    scopus 로고
    • Resistance and escape from antiangiogenesis therapy: Clinical implications and future strategies
    • 23008289 1:CAS:528:DC%2BC38XhvValtbfK 3488272
    • Bottsford-Miller JN, Coleman RL, Sood AK (2012) Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30:4026-4034
    • (2012) J Clin Oncol , vol.30 , pp. 4026-4034
    • Bottsford-Miller, J.N.1    Coleman, R.L.2    Sood, A.K.3
  • 24
    • 84868712956 scopus 로고    scopus 로고
    • Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients
    • 23154434 1:CAS:528:DC%2BC38XhvVyrs7rL
    • Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, Giunta V, De Amici M (2013) Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 84:115-122
    • (2013) Oncology , vol.84 , pp. 115-122
    • Porta, C.1    Paglino, C.2    Imarisio, I.3    Ganini, C.4    Sacchi, L.5    Quaglini, S.6    Giunta, V.7    De Amici, M.8
  • 27
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • 18650835 1:CAS:528:DC%2BD1cXovV2lsrk%3D 2874834
    • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
    • (2008) Nat Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.